Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer. - Wikidata - wikimedia - TriplyDB

Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer.

Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer.

http://www.wikidata.org/entity/Q35151114

about

ALK evaluation in the world of multiplex testing: Network Genomic Medicine (NGM): the Cologne model for implementing personalised oncology Tackling ALK in non-small cell lung cancer: the role of novel inhibitors Molecular Pathology and Personalized Medicine: The Dawn of a New Era in Companion Diagnostics-Practical Considerations about Companion Diagnostics for Non-Small-Cell-Lung-Cancer Fibroblast Growth Factor Receptor 1 and Related Ligands in Small-Cell Lung Cancer Genomic Landscape Survey Identifies SRSF1 as a Key Oncodriver in Small Cell Lung Cancer Patients harboring EGFR mutation after primary resistance to crizotinib and response to EGFR-tyrosine kinase inhibitor.Sensitive and affordable diagnostic assay for the quantitative detection of anaplastic lymphoma kinase (ALK) alterations in patients with non-small cell lung cancer.Next-generation sequencing facilitates detection of the classic E13-A20 EML4-ALK fusion in an ALK-FISH/IHC inconclusive biopsy of a stage IV lung cancer patient: a case report.Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative.Efficacy of D5F3 IHC for detecting ALK gene rearrangement in NSCLC patients: a systematic review and meta-analysis.ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma.Detection of ALK rearrangements in lung cancer patients using a homebrew PCR assay Performance of a RT-PCR Assay in Comparison to FISH and Immunohistochemistry for the Detection of ALK in Non-Small Cell Lung Cancer.ALK and ROS1 testing on lung cancer cytologic samples: Perspectives.Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy.Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice.Lung Cancer Biomarkers.Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer.Lung cancer as a paradigm for precision oncology in solid tumours.ALK in Non-Small Cell Lung Cancer (NSCLC) Pathobiology, Epidemiology, Detection from Tumor Tissue and Algorithm Diagnosis in a Daily Practice.ALK+ lung adenocarcinoma in never smokers and long-term ex-smokers: prevalence and detection by immunohistochemistry and fluorescence in situ hybridization.Custom Gene Capture and Next-Generation Sequencing to Resolve Discordant ALK Status by FISH and IHC in Lung Adenocarcinoma.Screening for ALK Rearrangements in Lung Cancer: Time for a New Generation of Diagnostics?Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches Liquid biopsy in the practice of neo-oncology Next-Generation Sequencing and Immunohistochemistry as Future Gold Standard of ALK Testing in Lung Cancer?Immunohistochemistry for predictive biomarkers in non-small cell lung cancer.Comparison of ALK status between primary and corresponding lymph node metastatic tumors in lung cancer patients.Dual drive coexistence of EML4-ALK and TPM3-ROS1 fusion in advanced lung adenocarcinoma.Anaplastic Lymphoma Kinase Testing: IHC vs. FISH vs. NGS.A comparison of ALK gene rearrangement and ALK protein expression in primary lung carcinoma and matched metastasis.Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer.CEP72-ROS1: A novel ROS1 oncogenic fusion variant in lung adenocarcinoma identified by next-generation sequencing.Resistance mechanisms to targeted therapies in ROS1+ and ALK+ non-small cell lung cancer.[Statement of the German Society for Pathology and the working group thoracic oncology of the working group oncology/German Cancer Society on ALK testing in NSCLC: Immunohistochemistry and/or FISH?].Clinical outcome study of crizotinib in immunohistochemistry-proven echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene among Indian patients with adenocarcinoma lung.Targeted next-generation-sequencing for reliable detection of targetable rearrangements in lung adenocarcinoma-a single center retrospective study.Simultaneous VENTANA IHC and RT-PCR testing of ALK status in Chinese non-small cell lung cancer patients and response to crizotinib.Significance and evaluation of anaplastic lymphoma kinase by immunohistochemistry in non-small cell lung cancer.NSCLC molecular testing in Central and Eastern European countries.

P2860

Q26738387-1D290B19-E029-4A82-9184-DC69CD7386D8 Q26740329-D52A75C3-95AE-4644-A804-DE281D71CF24 Q26771116-A1C8DAEE-EC28-4817-BA8C-565EB51C9313 Q35743009-B2AD8831-97F6-4088-A543-EF6A8E30304F Q35993683-328DAF0A-9E49-493E-8BF2-C700AF0F8E6B Q36462950-FEB60FFF-3E33-4FBA-B219-24F975C1D48F Q37392933-B7FA4913-014D-4359-8560-654E6C12ED5D Q37424085-62A24CF4-4DE7-4B3E-BE3E-00E7DDE456A5 Q37665697-12EE9E24-28D7-4918-803F-4297CBA5D48C Q37688499-0633C6D1-E4C7-4350-A208-CBD6E890F567 Q37696243-7EB02DCB-2610-4BB2-8AE7-2EADD64E4B77 Q37702598-E5A953C0-0D22-453F-998C-DCE7EBA29D28 Q38649524-130615D0-45BC-4DF6-A8D0-3C64BED0AFD3 Q38651989-4CE5FF6A-A925-40B6-BC2A-9F2AEC77638E Q38663460-336C2252-EA2D-4E37-BCB5-31EE7F8DB0D8 Q38816700-0D0317DB-B869-41DB-8CAB-7C37D9074C76 Q39027394-744A5172-25A4-453A-BD85-9ADD595BF0C5 Q39278116-941720A9-83AC-455E-9BD5-49AB74923FF9 Q39449763-4F33AFE4-0FCF-4FFB-B29F-DBD253FDE1F8 Q40084048-90C19F96-20E5-486D-947A-FA5A2E9806FB Q40513502-DCEC4D0A-05C2-4D77-A35A-8A42CFEC20B4 Q40523842-7CD1934C-94D2-43CB-B39B-D66297A16E5F Q42117389-FBB6218A-2240-4D73-AC8A-AE766ED34F1A Q42286165-7A19CBF2-213B-4A90-953B-B82D032053DA Q42369300-9D9C3D08-6EE6-461F-9A83-276C6C5503DB Q42415357-8B934BF9-D5DB-4D97-ADC5-033E2109CDB7 Q47140225-E0C9FCA4-D960-4078-8ED5-67894693E4DA Q47220523-EB3AF5B8-8A08-4702-BD16-AC1C3C9A93ED Q47281800-8857D691-F0C6-4624-8A03-8B9810B65DCC Q47578326-6B77CDF5-8323-47C1-A992-8D0B6E7E8D41 Q48108243-AB8448FA-4A72-42A3-AE45-6D2A377ACA52 Q48254761-431149DA-0B0D-448A-AE5E-FB173549C581 Q52666918-75313D5D-F3BB-4DC9-9D68-5498A8270A4E Q52720230-300EC358-C70A-406D-BBB9-597947D847AA Q52854883-AE9843C2-0EB9-45A2-84D2-2688D0C8F9E8 Q54118554-5AB7AE3B-811D-4468-A93A-D8C979A587A4 Q54960911-D2CB6305-4C4B-4530-B4ED-9DD30E0D3814 Q54983714-61899EE0-D48A-46C4-B493-673E05A11671 Q55030710-47C06BFC-E1E5-4736-8395-220CC261235B Q55284375-09204284-D052-4EF1-A846-D9CEF64B2BAB

P2860

Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer.

http://www.wikidata.org/entity/Q35151114

description

2015 nî lūn-bûn

@nan

2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Fluorescence in situ hybridiza ...... rearrangement in lung cancer.

@ast

Fluorescence in situ hybridiza ...... rearrangement in lung cancer.

@en

type

label

Fluorescence in situ hybridiza ...... rearrangement in lung cancer.

@ast

Fluorescence in situ hybridiza ...... rearrangement in lung cancer.

@en

prefLabel

Fluorescence in situ hybridiza ...... rearrangement in lung cancer.

@ast

Fluorescence in situ hybridiza ...... rearrangement in lung cancer.

@en

P1433

Q35151114-E4F8EEA8-5207-409C-A06D-241917EBF2A1

P1476

Q35151114-DA523106-8160-4128-923B-971182EBBD08

P2093

Q35151114-1060ED5F-688F-4103-A124-875814923572

Q35151114-1D4E6078-4F0D-4B59-B4B9-BC8F8B7DDF89

Q35151114-1FF6F4A1-49FA-4EA4-A199-32ED265E6292

Q35151114-2A3F9687-0813-4FDB-8D67-355E26EDE643

Q35151114-3E5E7AE4-6969-4950-8B21-18DEB9C650A7

Q35151114-59EC9D13-DDA3-46EC-88F2-9416E5C42BA3

Q35151114-7098A3B8-A84B-4A58-928A-8E3E15E07F83

Q35151114-83F2AF34-F2A9-4516-A3E7-F420184E587E

Q35151114-8D8BFFA7-E84D-40C2-9A33-65D4462AD7B9

Q35151114-93CF3033-68E5-42EA-8665-D30A29AA3159

P2860

Q35151114-01F4126E-6F70-44BB-97E0-C114DF81DDE5

Q35151114-0357B1A1-1714-4A09-A034-AA454786404A

Q35151114-054E0BA3-CA16-4130-85CB-B950EE551D34

Q35151114-06A06496-95B0-4A54-A8D8-0F4D56945B6B

Q35151114-0EA65E82-59B8-4FD0-8CF8-AF50D8229D9D

Q35151114-28F1AC23-CB83-4F70-BF27-87F763FDA2FF

Q35151114-2C8261D4-1EA7-4768-9095-BD2774670A1A

Q35151114-42735A1A-474A-4714-97C4-83DF9ECDDC6C

Q35151114-46C611ED-A079-46FE-AB0B-79AE64D40D5A

Q35151114-4709D211-D503-495A-B408-21C94CE07309

P304

Q35151114-18E47651-6CFF-4554-BE83-F276F3A894E3

P31

Q35151114-7E2CB29D-36EB-418B-9459-7997DA7AADDF

P356

Q35151114-2A5EAFBB-78D4-4F39-98E1-AAAEC15D3519

P433

Q35151114-CFD945C1-2891-4A07-BE55-2D092C1E36F5

P478

Q35151114-9118C579-5EC8-43AB-9DC6-AC5467E0346C

P577

Q35151114-A5257AC3-5606-4A2B-A9A2-836C08391B72

P698

Q35151114-E8EE5CD4-809F-4726-A56A-0ADDB9764BB4

P921

Q35151114-4971DE55-552D-439D-9E46-A52349519F35

P932

Q35151114-A1A36179-DA3A-4E11-9CB0-A8DB7D352A43

P356

THEONCOLOGIST.2014-0389

P1433

P1476

Fluorescence in situ hybridiza ...... rearrangement in lung cancer.

@en

P2093

Addie Dvir

http://www.w3.org/2001/XMLSchema#string

Doron Lipson

http://www.w3.org/2001/XMLSchema#string

Fred R Hirsch

http://www.w3.org/2001/XMLSchema#string

Gary A Palmer

http://www.w3.org/2001/XMLSchema#string

Lior Soussan-Gutman

http://www.w3.org/2001/XMLSchema#string

Marina Pekar-Zlotin

http://www.w3.org/2001/XMLSchema#string

Maya Ilouze

http://www.w3.org/2001/XMLSchema#string

Murry Wynes

http://www.w3.org/2001/XMLSchema#string

Nir Peled

http://www.w3.org/2001/XMLSchema#string

Paul A Bunn

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Cancer statistics, 2012

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

A mouse model for EML4-ALK-positive lung cancer

KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer.

A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry.

Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population.

Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression

P304

316-322

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1634/THEONCOLOGIST.2014-0389

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P577

2015-02-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25721120

http://www.w3.org/2001/XMLSchema#string

P921

immunohistochemistry

P932

4350802

http://www.w3.org/2001/XMLSchema#string